C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding C4 Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 100 | 1 | 84 | −15 |
| Shares | 34.2M | 1.85K | 34.5M | +299.1K (+0.9%) |
| Value | $94.1M | $15.0K | $64.5M | −$29.6M (−31.5%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held C4 Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,019,230 | $1.90M | 1.25% |
| M&T Bank Corp | 140,020 | $260.2K | 0.00% |
| Tudor Investment Corp Et Al | 15,223 | $28.3K | 0.00% |
| CI Private Wealth, LLC | 12,695 | $23.6K | 0.00% |
| Advisor Group Holdings, Inc. | 1,000 | $1.86K | 0.00% |
| Syntax Research, Inc. | 1,000 | $1.86K | 0.00% |
| EverSource Wealth Advisors, LLC | 448 | $833 | 0.00% |
Sold out (22)
Institutions that held C4 Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Gsa Capital Partners LLP | 312,135 | $858.0K |
| Jane Street Group, LLC | 98,565 | $271.1K |
| Y-Intercept (Hong Kong) Ltd | 75,900 | $208.7K |
| Manufacturers Life Insurance Company, The | 65,195 | $179.3K |
| Squarepoint Ops LLC | 52,024 | $143.1K |
| TD Asset Management Inc | 48,453 | $133.2K |
| UBS Asset Management Americas Inc | 39,287 | $123.4K |
| Point72 Middle East FZE | 38,607 | $106.2K |
| State of Wyoming | 34,494 | $94.9K |
| Graham Capital Management, L.P. | 32,974 | $90.7K |
| Old Mission Capital LLC | 29,548 | $81.3K |
| Caxton Associates LP | 26,721 | $73.5K |
| Laurion Capital Management LP | 25,983 | $71.5K |
| PDT Partners, LLC | 21,432 | $58.9K |
| DRW Securities, LLC | 21,100 | $58.0K |
| Jump Financial, LLC | 17,915 | $49.3K |
| Dynamic Technology Lab Private Ltd | 12,708 | $35.0K |
| Balyasny Asset Management LLC | 11,686 | $32.1K |
| SEI Investments Co | 11,191 | $30.8K |
| Engineers Gate Manager LP | 10,900 | $30.0K |
| Erste Asset Management GmbH | 10,700 | $29.4K |
| New York State Common Retirement Fund | 320 | $880 |
Not filed for Q3 2023 yet (1)
Institutions that held C4 Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Endurance Wealth Management, Inc. | 1,850 | $15.0K |